AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders

#OncoResponse is participating in the 22nd Annual Needham Virtual Healthcare Conference from April 17th-20th, 2023. CEO Clifford Stocks is presenting a company overview today from 12:45-1:25pm EST. #EliteCancerResponders

PRESS RELEASE: #OncoResponse today presented preclinical data highlighting our identification of dual antagonist antibodies targeting LILRB1 and LILRB2 as potential anti-cancer immunotherapies at #AACR23 (AACR) in Orlando, Florida. #EliteCancerResponders oncoresponse.com/news-center/pr…

#OncoResponse CEO Clifford Stocks will be presenting at #LSINW23 (Life Science WA) on April 25th, representing OncoResponse during company presentations on Oncology & Rare Disease. Other companies include Umoja Biopharma, Cartography Biosciences, Presage Biosciences, @ChinookTx, and Kayothera.

#OncoResponse CEO Clifford Stocks presents today at #LSINW23 (Life Science WA), representing OncoResponse during company presentations on Oncology & Rare Disease. Other companies include Umoja Biopharma,Cartography Biosciences,Presage Biosciences,@ChinookTx,and Kayothera. #EliteCancerResponders

Happy Mother's Day to the real-life superheroes that inspire us every day! Join us in honoring and celebrating the diverse range of moms and caretakers who make a positive impact in our lives. Thank you for all you do, and we wish you a wonderful day celebrating with loved ones.

#OncoResponse awarded $13 million CPRIT grant to fund the advancement of OR502, a best-in-class anti-LILRB2 antibody poised to move to IND and clinical studies. #EliteCancerResponders oncoresponse.com/news-center/pr…

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced it has raised $14M in funding. bit.ly/3BCYn3z #OncoResponse #biotechnology #chatgptai #medtechproblems

#grants, awards ~Pulvinar Neuro awarded $3M NIH #Grant for #TranscranialStimulation research ~OncoResponse awarded $13M #funding from CPRIT + $14M from #investors ~NIH awards $14.4M to @NDRI_Resource in collab with University of Maryland School of Medicine, @AllChildrens

OncoResponse adds $27M to support advancement of novel #immunotherapy programs. Funds come from CPRIT grant, as well as existing investor syndicate. OR2805 in Phase 1 trial; OR502 moving to IND and clinic. Canaan’s Wende Hutton is on co's board. oncoresponse.com/news-center/pr…

#OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy. Led by @RiverVest and including ARCH Venture Partners, Canaan, 3B Future Health Fund, Bering Capital, Takeda Ventures, InterVest, and others. #EliteCancerResponders

CEO Clifford Stocks and CFO Chris Russell are proud to participate in the SVB Securities BioPharma Private Company Connect occurring May 24-25, 2023. We hope for exciting discussions with interested parties as we continue to seek additional investors. #EliteCancerResponders

Today, we pause to honor those who bravely served and are no longer with us. Their selflessness and dedication have left an enduring impact. On this Memorial Day, let us reflect on their sacrifices and express our deepest gratitude. #MemorialDay

CEO Clifford Stocks and CMO Bob Lechleider enjoying their time in Chicago at the ASCO annual meeting! #ASCO23 #EliteCancerResponders

oncoresponse.com/news-center/pr… #OncoResponse is pleased to announce the appointment of Carol Gallagher, PharmD, to our Board of Directors as an Independent Director. She currently serves on several private and public boards and is a venture advisor at NEA. #EliteCancerResponders

PRESS RELEASE: #OncoResponse Announces Preclinical Data Highlighting #OR502 anti-LILRB2 Antibody and #OR641 Dual anti-LILRB2/1 Antibody at SITC 2023 #SITC23 #EliteCancerResponders Posters available now: oncoresponse.com/publications/p… oncoresponse.com/news-center/pr…

PRESS RELEASE: #OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of #OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer. See the full release here: oncoresponse.com/news-center/pr… #EliteCancerResponders

#OncoResponse CEO Clifford Stocks will be giving a company presentation at Life Science WA's Life Science Innovation Northwest 2024 in Seattle this week #EliteCancerResponders #LSINW24

PRESS RELEASE: #OncoResponse to Present Phase 1 Results of Clinical Study of #OR502, anti-LILRB2 Antibody, at SITC 2024. See the full release here: oncoresponse.com/news-center/pr… #EliteCancerResponders

PRESS RELEASE: #OncoResponse Announces Phase 1 Results of Clinical Trial of #OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer. Results available in Late-Breaking Poster Presentation at SITC 2024. See the full release: oncoresponse.com/news-center/pr… #EliteCancerResponders